p21 expression in colorectal carcinomas: A study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations

Virchows Archiv

Volumn 435, Issue 6, 1999, Pages 559-565

  Girlando, S ^a   Slomp, P ^a   Caffo, O ^a   Amichetti, M ^a   Togni, R ^a   Dvornik, G ^a   Tomio, L ^a   Galligioni, E ^a   Dalla Palma, P ^a   Barbareschi, M ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Colon; Human; Immunohistochemistry; p21; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER STAGING; COLORECTAL CARCINOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; STAINING; TUMOR SUPPRESSOR GENE;

EID: 0032733852     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050441     Document Type: Article

References (46)

1. 1. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JFR (1995) Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72:1259-1266
2. 2. Baas IO, Mulder J-W, Offerhaus GJA, Vogelstein B (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12
3. 3. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dallapalma P, Harris AL (1996) p21(WAF1) immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 74:208-215
4. 4. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Palma PD, Harris A (1996) Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27:1149-1155
5. 5. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL (1997) Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181:140-145
6. 6. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Leek R, Dalla Palma P, Harris AL, Barbareschi M (1996) Prognostic value of p21WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long term follow-up. Clin Cancer Res 2:1591-1599
7. 7. Cayrol C, Knibiehler M, Ducommun B (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16:311-320
8. 8. Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 6:1727-1731
9. 9. Clahsen PC, Vandevelde CJH, Duval C, Pallud C, Mandard AM, Delobellederoide A, vandenBroek L, Sahmoud TM, Vandevijver MJ (1998) p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479
10. 10. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitzdrager BJ (1998) Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 77:515-521
11. 11. Cox LS (1997) Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21(Cip1/WAF1/Sdi1). J Pathol 183:134-140
12. 12. Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, Boiocchi M, Fletcher CD (1997) Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol 181:8-13
13. 13. Doglioni C, Pelosio P, Laurino L, Macrì E, Meggiolaro E, Favretti F, Barbareschi M (1996) p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179:248-253
14. 14. El-Deiry WS, Tokino T, Velculsecu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
15. 15. El-Deiry WS, Tokino T, Waldman T, et al (1995) Topological control of p21 Waf1/Cip1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919
16. 16. Elledge RM, Gray R, Mansour E, Yu YY, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC (1995) Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256
17. 17. Ellis PA, Lonning PE, Borresendale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M (1997) Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 76:480-485
18. 18. Fujiwara T, Stolker JM, Watanabe T, Rashid A, Longo P, Eshleman JR, Booker S, Lynch HT, Jass JR, Green JS, Kim H, Jen J, Vogelstein B, Hamilton SR (1998) Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 153:1063-1078
19. 19. Fukuchi K, Tomoyasu S, Nakamaki T, Tsuruoka N, Gomi K (1998) DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells Bba. Mol Cell Res 1404:405-411
20. 20. Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, Shiff SJ (1996) The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893-901
21. 21. Hao XP, Du MQ, Bishop AE, Talbot IC (1998) Imbalance between proliferation and apoptosis in the development of colorectal carcinoma. Virchows Arch 433:523-527
22. 22. Heidenreich A, Schenkman NS, Sesterhenn IA, Mostofi KF, Moul JW, Srivastava S, Engelmann UH (1998) Immunohistochemical and mutational analysis of the p53 tumour suppressor gene am1 the bcl-2 oncogene in primary testicular germ cell tumours. APMIS 106:90-99
23. 23. Hisaoka M, Okamoto S, Morimitsu Y, Tsuji S, Hashimoto H (1998) Dermatofibrosarcoma protuberans with fibrosarcomatous areas - molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch 433:323-329
24. 24. Ilyas M, Tomlinson IPM, Novelli MR, Hanby A, Bodmer WF, Talbot IC (1996) Clinico-pathological features and p53 expression in left-sided sporadic colorectal cancers with and without microsatellite instability. J Pathol 179:370-375
25. 25. Jessup JM, Loda M, Bleday R (1998) Clinical and molecular prognostic factors in sphincter-preserving surgery for rectal cancer. Semin Radiat Oncol 8:54-69
26. 26. Jung JM, Bruner JM, Ruan SB, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W (1995) Increased levels of p21(WAF1/Cip1) in human brain tumors. Oncogene 11:2021-2028
27. 27. Li XS, Rishi AK, Shao ZM, Dawson MI, Jong L, Shroot B, Reichert U, Ordonez J, Fontana JA (1996) Posttranscriptional regulation of p21(WAF1/CIP1) expression in human breast carcinoma cells. Cancer Res 56:5055-5062
28. 28. Lowe SW, Bodis S, Mcclatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-811
29. 29. Ludwig RL, Bates S, Vousden KH (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16:4952-4960
30. 30. Marchetti A, Buttitta F, Pellegrini S, Diella F, Campani D, Cecchetti D, Merlo C, Callahan R, Bistocchi M (1993) p53 mutations and histological type of invasive breast carcinoma. Cancer Res 53:4665-4669
31. 31. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Dallapalma P, Bevilacqua G (1996) p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12:1319-1324
32. 32. Milner J (1995) DNA damage, p53 and anticancer therapies. Nat Med 1:879-888
33. 33. Morin P, Vogelstein B, Kinzler KW (1996) Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 93:7950-7954
34. 34. Nadal A, Jares P, Cazorla M, Fernandez PL, Sanjuan X, Hernandez L, Pinyol M, Aldea M, Mallofre C, Muntane J, Traserra J, Campo E, Cardesa A (1997) P21(WAF1/Cip1) expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 183:156-163
35. 35. Polyak K, Hamilton SR, Vogelstein B, Kinzler KW (1996) Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol 149:381-387
36. 36. Rey MJ, Fernandez PL, Jares P, Munoz M, Nadal A, Peiro N, Nayach I, Mallofre C, Muntane J, Campo E, Estape J, Cardesa A (1998) p21(WAF1/Cip1) is associated with cyclin D1(CCND1) expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol 184:265-271
37. 37. Ropponen KM, Kellokoski JK, Lipponen P, Pietilainen T, Eskelinen M, Alhava E, Kosma VM (1999) p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer (in press)
38. 38. Rozan S, Vicent Salomon A, Zafrani B, Validire P, DeCremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P, Sastre Garau X (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79:27-33
39. 39. Seta T, Imazeki F, Yokosuka O, Saisho H, Suzuki T, Koide Y, Isono K (1998) Expression of p53 and p21(WAF1/CIP1) proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. Dig Dis Sci 43:279-289
40. 40. Sinicorpe FA, Roddey G, Lemonie M, Ruan S, Stephens LC, Fraizer ML, Shen Y, Zhang W (1998) Loss of p21WAF1/CIP1 protein expression accompanies progression of sporadic colo-rectal neoplasms but not hereditary non-polyposis colorectal cancers. Clin Cancer Res 4:1251-1261
41. 41. Slebos RJC, Baas IO, Clement M, Polak M, Mulder J-W, van der Bergh FM, Hamilton SR, Offerhaus GJA (1996) Clinical and pathological associations with p53 tumor-suppressor gene mutations and expression of p21WAF1/CIP1 in colorectal carcinomas. Br J Cancer 74:165-171
42. 42. Stinchcomb DT (1995) Constraining the cell cycle: regulating cell division and differentiation by gene therapy. Nat Med 1:1004-1006
43. 43. Tron VA, Tang LR, Yong WP, Trotter MJ (1996) Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21(waf-1) in human cutaneous squamous cell carcinoma. Am J Pathol 149:1139-1146
44. 44. Villuendas R, Pezzella F, Gatter K, Algara P, Sanchezbeato M, Martinez P, Martinez JC, Munoz K, Garcia P, Sanchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA (1997) p21(WAF1/CIP1) and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 181:51-61
45. 45. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E (1996) Expression of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 180:122-128
46. 46. Zeng YX, El-Deiry WS (1996) Regulation of p21(WAF1/CIP1) expression by p53-independent pathways. Oncogene 12:1557-1564